XNYS · Healthcare · Medical Devices
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-06 | Q1 2026 | 0.16 | -0.01 | -106.25% | $0 | ❌ Miss | +0.00% | -5.25% | — |
| 2026-02-04 | Q4 2025 | 0.78 | 0.80 | +2.56% | $5.29B | ✅ Beat | +0.63% | -2.69% | -5.50% |
| 2025-10-22 |
| Q3 2025 |
| 0.71 |
| 0.75 |
| +5.63% |
| $5.07B |
| ✅ Beat |
| — |
| — |
| — |
| 2025-07-23 | Q2 2025 | 0.72 | 0.75 | +4.17% | $5.06B | ✅ Beat | — | — | — |
| 2025-04-23 | Q1 2025 | 0.67 | 0.75 | +11.94% | $4.66B | ✅ Beat | — | — | — |
| 2025-02-05 | Q4 2024 | 0.66 | 0.70 | +6.06% | $4.56B | ✅ Beat | — | — | — |
| 2024-10-23 | Q3 2024 | 0.59 | 0.63 | +6.78% | $4.21B | ✅ Beat | — | — | — |
| 2024-07-24 | Q2 2024 | 0.58 | 0.62 | +6.90% | $4.12B | ✅ Beat | — | — | — |
Showing last 8 quarters.